Skip to main content
. 2016 Aug 3;8(9):1097–1117. doi: 10.2217/imt-2016-0021

Figure 3. . Event-free survival for 226 patients randomized into the treatment groups.

Figure 3. 

13-cis-retinoic acid (CRA) alone (standard therapy) versus immunotherapy (ch14.18 monoclonal antibody + GM-CSF + IL-2 + CRA) for high-risk neuroblastoma. Data are shown for event-free survival for all 226 patients. The estimated survival (±SE) at 2 years is indicated in the plot.

Adapted with permission from [66] © Massachusetts Medical Society (2010). Reprinted with permission from Massachusetts Medical Society.